Approximately 30% of primary glioblastomas show TP53 mutations associated with gain-of-function, loss-of-function, and dominant-negative effects (Ham et al., 2019, Marutani et al., 1999, Wang et al., 2004, Wang et al., 2013). This evidence concerns the gene TP53 and glioblastoma.